P2D Bioscience (P2D) is a specialty pharmaceutical company focused on developing innovative drugs that fulfill unmet medical needs in the treatment of central nervous system (CNS) and inflammatory disorders, and cancer.   

At P2D, our experienced drug development team utilizes our in-depth understanding of the clinical treatment of these disorders to efficiently build a product portfolio of therapeutics with an improved likelihood for clinical success. Our goal is to advance a product candidate through preclinical development and clinical proof-of-concept by producing powerful and compelling clinical data and then seeking partners to complete the clinical development and commercialization process.

P2D currently has a pipeline of five drug candidates to treat attention deficit/hyperactivity disorder (ADHD), Chronic Obstructive Pulmonary Disease (COPD) and Alzheimer’s disease (AD).